VitaMK7® (Vitamin K2 as MK-7 — Gnosis)

Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

VitaMK7® is a natural vitamin K2 in the menaquinone-7 (MK-7) form from Gnosis, produced by fermentation of Bacillus subtilis natto and standardized to over 99% of the active all-trans isomer. Vitamin K2 directs calcium into bones and away from arteries, supporting both bone strength and cardiovascular health.

Studied Dose Commonly 90 to 180 mcg of MK-7 per day.
Active Compound Vitamin K2 as menaquinone-7 (MK-7), greater than 99% all-trans isomer, from natto fermentation.

Benefits

Bone strength

In a 3-year randomized trial in postmenopausal women, low-dose MK-7 helped decrease age-related bone loss, supporting bone mineral density.

Arterial flexibility

Vitamin K2 activates a protein that keeps calcium out of artery walls, supporting flexible, healthy arteries.

Calcium routing

MK-7 helps direct dietary calcium into bone rather than soft tissue, complementing calcium and vitamin D.

Mechanism of action

1

Osteocalcin activation

MK-7 carboxylates (activates) osteocalcin, the protein that binds calcium into the bone matrix, strengthening bone.

2

Matrix Gla protein activation

MK-7 activates matrix Gla protein, which inhibits calcium deposition in artery walls, protecting cardiovascular tissue.

Clinical trials

1
MK-7 and Bone Loss — 3-Year RCT
PubMed

Three-year randomized trial of low-dose menaquinone-7 (MK-7) supplementation in healthy postmenopausal women. (Knapen et al. 2013, Osteoporosis International)

Healthy postmenopausal women.

Low-dose MK-7 helped decrease bone loss at the spine and femoral neck versus placebo.

Side effects and drug interactions

Common Potential side effects

GENERALLY WELL-TOLERATED at recommended doses.
Vitamin K2 interferes with warfarin-type blood thinners; do not use without medical supervision.
Mild digestive upset is occasionally reported.

Important Drug interactions

Warfarin / vitamin-K-antagonists — directly opposes these blood thinners; medical supervision required.
Generally compatible with other medications.
Tell your doctor if you take anticoagulants.

Frequently asked questions about VitaMK7® (Vitamin K2 as MK-7 — Gnosis)

What is VitaMK7® (Vitamin K2 as MK-7 — Gnosis)?

VitaMK7® is a natural vitamin K2 in the menaquinone-7 (MK-7) form from Gnosis, produced by fermentation of Bacillus subtilis natto and standardized to over 99% of the active all-trans isomer. Vitamin K2 directs calcium into bones and away from arteries, supporting both bone strength and cardiovascular health.

What is the recommended dosage of VitaMK7® (Vitamin K2 as MK-7 — Gnosis)?

The clinically studied dose for VitaMK7® (Vitamin K2 as MK-7 — Gnosis) is Commonly 90 to 180 mcg of MK-7 per day.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is VitaMK7® (Vitamin K2 as MK-7 — Gnosis) used for?

VitaMK7® (Vitamin K2 as MK-7 — Gnosis) is studied for bone strength, arterial flexibility, calcium routing. In a 3-year randomized trial in postmenopausal women, low-dose MK-7 helped decrease age-related bone loss, supporting bone mineral density.

Are there side effects from taking VitaMK7® (Vitamin K2 as MK-7 — Gnosis)?

Reported potential side effects may include: GENERALLY WELL-TOLERATED at recommended doses. Vitamin K2 interferes with warfarin-type blood thinners; do not use without medical supervision. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Is VitaMK7® (Vitamin K2 as MK-7 — Gnosis) safe to take?

Whether VitaMK7® (Vitamin K2 as MK-7 — Gnosis) is safe depends on the dose, your overall health, and any medications you take. At studied doses, reported side effects can include: GENERALLY WELL-TOLERATED at recommended doses. It may also interact with certain medications. VitaMK7® (Vitamin K2 as MK-7 — Gnosis) is not suitable for everyone — consult a healthcare provider before use if you are pregnant or breastfeeding, have a medical condition, or take prescription medications.

References(1 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Knapen MH, Drummen NE, Smit E, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013;24(9):2499-507..PubMedUsed to support: RCT supporting bone-density benefit of MK-7.